Kepler Capital analyst Maja Pataki maintained a Hold rating on Qiagen (QGEN – Research Report) on November 6 and set a price target of €38.00. The company’s shares closed yesterday at $39.22.
According to TipRanks, Pataki is an analyst with an average return of -16.4% and a 26.98% success rate.
In addition to Kepler Capital , Qiagen also received a Hold from TD Cowen’s Daniel Brennan in a report issued on October 31. However, on November 1, Morgan Stanley maintained a Buy rating on Qiagen (NYSE: QGEN).
See the top stocks recommended by analysts >>
QGEN market cap is currently $8.94B and has a P/E ratio of 27.01.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QGEN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Qiagen (QGEN) Company Description:
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
Read More on QGEN:
- Qiagen, Element Biosciences partner to offer sequencing workflows
- Qiagen price target lowered to $46 from $50 at Baird
- Qiagen backs FY23 sales view of at least $1.97B, consensus $1.97B
- Qiagen reports Q3 EPS 50c, consensus 48c
- QIAGEN exceeds outlook for Q3 2023 with 5% CER sales growth in non-COVID products and adjusted EPS of $0.50 CER
